Pyrotinib as neoadjuvant therapy for HER2+breast cancer: A multicenter, randomized, controlled, phase II trial.

doi:10.1200/JCO.2021.39.15_suppl.574

HFCAS OpenIR

	Pyrotinib as neoadjuvant therapy for HER2+breast cancer: A multicenter, randomized, controlled, phase II trial.
	Ding, Xiaowen ; Mo, Wenju ; Xie, Xiaohong ; Wang, Ouchen ; Ding, Yuqin ; Zhao, Shuai ; He, Xiangming ; Feng, Weiliang ; Zou, Dehong ; Yang, Hongjian
	2021-05-20
发表期刊	JOURNAL OF CLINICAL ONCOLOGY
ISSN	0732-183X
DOI	10.1200/JCO.2021.39.15_suppl.574
收录类别	SCI
语种	英语
资助项目	Jiangsu Hengrui Pharmaceuticals Co., Ltd.
项目资助者	Jiangsu Hengrui Pharmaceuticals Co., Ltd.
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000708120600084
出版者	LIPPINCOTT WILLIAMS & WILKINS
引用统计	被引频次：2[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/126495
专题	中国科学院合肥物质科学研究院
作者单位	1.Univ Chinese Acad Sci, Chinese Acad Sci, Inst Canc & Basic Med ICBM, Canc Hosp,Zhejiang Canc Hosp, Hangzhou, Peoples R China 2.Zhejiang Hosp Tradit Chinese Med, Hangzhou, Peoples R China 3.Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Peoples R China
推荐引用方式 GB/T 7714	Ding, Xiaowen,Mo, Wenju,Xie, Xiaohong,et al. Pyrotinib as neoadjuvant therapy for HER2+breast cancer: A multicenter, randomized, controlled, phase II trial.[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39.
APA	Ding, Xiaowen.,Mo, Wenju.,Xie, Xiaohong.,Wang, Ouchen.,Ding, Yuqin.,...&Yang, Hongjian.(2021).Pyrotinib as neoadjuvant therapy for HER2+breast cancer: A multicenter, randomized, controlled, phase II trial..JOURNAL OF CLINICAL ONCOLOGY,39.
MLA	Ding, Xiaowen,et al."Pyrotinib as neoadjuvant therapy for HER2+breast cancer: A multicenter, randomized, controlled, phase II trial.".JOURNAL OF CLINICAL ONCOLOGY 39(2021).